Skip to main content
Publications
Rebordosa C , Thomsen RW, Tave AK, Madsen M, Beachler DC, Martinez D , Garcia-Esteban R , Plana E , Tormos A , Farsani SF, Perez-Gutthann S , Pladevall-Vila M . Liver, renal, genitourinary, and diabetic ketoacidosis risks among new users of empagliflozin versus DPP-4 inhibitors in patients with type 2 diabetes: post-authorisation safety study based on multinational cohorts . Diabetes Obes Metab. 2024 Apr;26(4):1291-304. doi: 10.1111/dom.15429
Samelson EJ, Miller PD, Christiansen C, Daizedeh NS, Grazette L, Anthony MS , Egbuna O, Wang A, Siddhanti SR, Cheung AM, Franchimont N, Kiel DP. RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk . J Bone Miner Res. 2014 Feb;29(2):450-7. doi: 10.1002/jbmr.2043
Quteineh L, Vandenberghe F, Gholam Rezaee M, Choong E, Saigi-Morgui N , Delacretaz A, Preisig M, von Gunten A, Conus P, Eap C. CRTC3 polymorphisms are not associated with obesity in Swiss psychiatric populations . Poster presented at the 22nd European Congress of Psychiatry; March 2014. Munich, Germany. [abstract] The european journal of psychiatry. 2014; 29:1.